Methyclothiazide

{{DrugProjectFormSinglePage |authorTag=

Gerald Chi

|genericName=

Methyclothiazide

|aOrAn=

a

|drugClass=

thiazide-like diuretic

|indication=

hypertension and edema associated with congestive heart failure, hepatic cirrhosis, renal dysfunction, and corticosteroid and estrogen therapy

|hasBlackBoxWarning=

|adverseReactions=

hypotension, rash, hyperuricemia, hypokalemia, nausea, cramp, dizziness, and headache

|blackBoxWarningTitle= Title

|blackBoxWarningBody= ConditionName:

• Content

|fdaLIADAdult=

• Methyclothiazide tablets are administered orally. Therapy should be individualized according to patient response. This therapy should be titrated to gain maximal therapeutic response as well as the minimal dose possible to maintain that therapeutic response.

Edema

• Dosing Information

• The usual adult dose ranges from 2.5 mg to 10 mg once daily.
• Maximum effective single-dose is 10 mg; larger single doses do not accomplish greater diuresis, and are not recommended.

Hypertension

• Dosing Information

• The usual adult dose ranges from 2.5 mg to 5 mg once daily.
• If control of blood pressure is not satisfactory after 8 to 12 weeks of therapy with 5 mg once daily, another antihypertensive drug should be added. Increasing the dosage of methyclothiazide tablets will usually not result in further lowering of blood pressure.
• Methyclothiazide tablets may be either employed alone for mild to moderate hypertension or concurrently with other antihypertensive drugs in the management of more severe forms of hypertension. Combined therapy may provide adequate control of hypertension with lower dosage of the component drugs and fewer or less severe side effects.
• When other antihypertensive agents are to be added to the regimen, this should be accomplished gradually. Ganglionic blocking agents should be given at only half the usual dose since their effect is potentiated by pretreatment with methyclothiazide tablets.

|offLabelAdultGuideSupport=

There is limited information regarding Off-Label Guideline-Supported Use of Methyclothiazide in adult patients.

|offLabelAdultNoGuideSupport=

There is limited information regarding Off-Label Non–Guideline-Supported Use of Methyclothiazide in adult patients.

|fdaLIADPed=

Safety and effectiveness in children have not been established.

|offLabelPedGuideSupport=

There is limited information regarding Off-Label Guideline-Supported Use of Methyclothiazide in pediatric patients.

|offLabelPedNoGuideSupport=

There is limited information regarding Off-Label Non–Guideline-Supported Use of Methyclothiazide in pediatric patients.

|contraindications=

• Anuria
• Hypersensitivity to this compound or other sulfonamide-derived drugs

|warnings=

• Methyclothiazide shares with other thiazides the propensity to deplete potassium reserves to an unpredictable degree.
• There have been isolated reports that certain non-edematous individuals developed severe fluid and electrolyte derangements after only brief exposure to normal doses of thiazide and non-thiazide diuretics.
• Thiazides should be used with caution in patients with renal disease or significant impairment of renal function, since azotemia may be precipitated and cumulative drug effects may occur.
• Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.
• Sensitivity reactions may occur in patients with a history of allergy or bronchial asthma.
• The possibility of exacerbation or activation of systemic lupus erythematosus has been reported.
• Hyperuricemia may occur or frank gout may be precipitated in certain patients receiving thiazide therapy.

Precautions

• All patients should be observed for clinical signs of electrolyte imbalances such as dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting.
• Hypokalemia may develop, especially with brisk diuresis, when severe cirrhosis is present, during concomitant use of corticosteroids or ACTH, or after prolonged therapy.
• Interference with adequate oral electrolyte intake will also contribute to hypokalemia. Hypokalemia may be avoided or treated by use of potassium supplements or foods with a high potassium content.
• Any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (as in liver disease or renal disease). Dilutional hyponatremia may occur in edematous patients in hot weather; appropriate therapy is water restriction rather than administration of salt, except in rare instances when the hyponatremia is life threatening. In actual salt depletion, appropriate replacement is the therapy of choice.
• Latent diabetes mellitus may become manifest during thiazide administration.
• The antihypertensive effects of the drug may be enhanced in the postsympathectomy patient.
• If progressive renal impairment becomes evident as indicated by a rising nonprotein nitrogen or blood urea nitrogen, a careful reappraisal of therapy is necessary with consideration given to withholding or discontinuing diuretic therapy.
• Thiazides may decrease urinary calcium excretion. Thiazides may cause intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Marked hypercalcemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for [[parathyroid]\] function.
• Thiazides may cause increased concentrations of total serum cholesterol, total triglycerides, and low-density lipoproteins in some patients. Use thiazides with caution in patients with moderate or high cholesterol concentrations and in patients with elevated triglyceride levels.

Laboratory Tests

• Initial and periodic determinations of serum electrolytes should be performed at appropriate intervals for the purpose of detecting possible electrolyte imbalances such as hyponatremia, hypochloremic alkalosis, and hypokalemia. Serum and urine electrolyte determinations are particularly important when a patient is vomiting excessively or receiving parenteral fluids.

|clinicalTrials=

There is limited information regarding Clinical Trial Experience of Methyclothiazide in the drug label.

Miscellaneous

|postmarketing=

There is limited information regarding Postmarketing Experience of Methyclothiazide in the drug label.

Miscellaneous

|drugInteractions=

• Drug

• Description

|useInPregnancyFDA=

• Pregnancy Category

|useInPregnancyAUS=

• Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Methyclothiazide in women who are pregnant.

|useInLaborDelivery= There is no FDA guidance on use of Methyclothiazide during labor and delivery.

|useInNursing= There is no FDA guidance on the use of Methyclothiazide with respect to nursing mothers.

|useInPed= There is no FDA guidance on the use of Methyclothiazide with respect to pediatric patients.

|useInGeri= There is no FDA guidance on the use of Methyclothiazide with respect to geriatric patients.

|useInGender= There is no FDA guidance on the use of Methyclothiazide with respect to specific gender populations.

|useInRace= There is no FDA guidance on the use of Methyclothiazide with respect to specific racial populations.

|useInRenalImpair= There is no FDA guidance on the use of Methyclothiazide in patients with renal impairment.

|useInHepaticImpair= There is no FDA guidance on the use of Methyclothiazide in patients with hepatic impairment.

|useInReproPotential= There is no FDA guidance on the use of Methyclothiazide in women of reproductive potentials and males.

|useInImmunocomp= There is no FDA guidance one the use of Methyclothiazide in patients who are immunocompromised.

|administration=

• Oral

• Intravenous

|monitoring=

There is limited information regarding Monitoring of Methyclothiazide in the drug label.

Condition1

• Description

|IVCompat=

There is limited information regarding IV Compatibility of Methyclothiazide in the drug label.

|overdose=

Acute Overdose

Signs and Symptoms

• Description

Management

• Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Methyclothiazide in the drug label.

|drugBox=

|mechAction=

|structure=

This image is provided by the National Library of Medicine.

|PD=

There is limited information regarding Pharmacodynamics of Methyclothiazide in the drug label.

|PK=

There is limited information regarding Pharmacokinetics of Methyclothiazide in the drug label.

|nonClinToxic=

There is limited information regarding Nonclinical Toxicology of Methyclothiazide in the drug label.

|clinicalStudies=

There is limited information regarding Clinical Studies of Methyclothiazide in the drug label.

Condition1

• Description

|howSupplied=

|fdaPatientInfo=

• Patients should inform their doctor if they have:

• Had an allergic reaction to methyclothiazide or other diuretics
• Asthma

• Kidney disease

• Liver disease
• Gout
• Systemic lupus erythematosus
• Had been taking other drugs such as cortisone, digitalis, lithium carbonate, or drugs for diabetes.

• The physician should inform patients of possible side effects and caution the patient to report any of the following symptoms of electrolyte imbalance; dryness of mouth, thirst, weakness, tiredness, drowsiness, restlessness, muscle pains or cramps, nausea, vomiting or increased heart rate.
• The physician should advise the patient to take this medication every day as directed. Physicians should also caution patients that drinking alcohol can increase the chance of dizziness.

|alcohol=

• Alcohol-Methyclothiazide interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

|brandNames=

• Aquatensen®
• Enduron®

|lookAlike=

• N/A

|drugShortage= }}

{{#subobject:

 |Page Name=Methyclothiazide
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage=
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Methyclothiazide
 |Label Name=Methyclothiazide11.png

}}

{{#subobject:

 |Label Page=Methyclothiazide
 |Label Name=Methyclothiazide11.png

}}